PL3447051T3 - Sposób otrzymywania inhibitora kinazy tyrozynowej i jego pochodnej - Google Patents

Sposób otrzymywania inhibitora kinazy tyrozynowej i jego pochodnej

Info

Publication number
PL3447051T3
PL3447051T3 PL17788792T PL17788792T PL3447051T3 PL 3447051 T3 PL3447051 T3 PL 3447051T3 PL 17788792 T PL17788792 T PL 17788792T PL 17788792 T PL17788792 T PL 17788792T PL 3447051 T3 PL3447051 T3 PL 3447051T3
Authority
PL
Poland
Prior art keywords
derivative
tyrosine kinase
kinase inhibitor
preparing tyrosine
preparing
Prior art date
Application number
PL17788792T
Other languages
English (en)
Inventor
Guaili Wu
Quanliang ZHANG
Yongxing Cao
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60160713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3447051(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jiangsu Hengrui Medicine Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of PL3447051T3 publication Critical patent/PL3447051T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL17788792T 2016-04-28 2017-04-27 Sposób otrzymywania inhibitora kinazy tyrozynowej i jego pochodnej PL3447051T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610274566 2016-04-28
PCT/CN2017/082164 WO2017186140A1 (zh) 2016-04-28 2017-04-27 一种制备酪氨酸激酶抑制剂及其衍生物的方法
EP17788792.4A EP3447051B1 (en) 2016-04-28 2017-04-27 Method for preparing tyrosine kinase inhibitor and derivative thereof

Publications (1)

Publication Number Publication Date
PL3447051T3 true PL3447051T3 (pl) 2022-03-14

Family

ID=60160713

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17788792T PL3447051T3 (pl) 2016-04-28 2017-04-27 Sposób otrzymywania inhibitora kinazy tyrozynowej i jego pochodnej

Country Status (13)

Country Link
US (2) US10793548B2 (pl)
EP (1) EP3447051B1 (pl)
JP (1) JP6947749B2 (pl)
CN (1) CN108290867B (pl)
BR (1) BR112018071617A2 (pl)
CA (1) CA3021471A1 (pl)
DK (1) DK3447051T3 (pl)
ES (1) ES2903416T3 (pl)
HU (1) HUE057402T2 (pl)
PL (1) PL3447051T3 (pl)
PT (1) PT3447051T (pl)
TW (1) TWI739825B (pl)
WO (1) WO2017186140A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108314639B (zh) * 2018-05-09 2019-04-30 山东铂源药业有限公司 化合物（e）-3-（1-甲基吡咯烷-2-基）-丙烯酸盐酸盐及合成方法
CN110960529A (zh) * 2018-09-30 2020-04-07 江苏恒瑞医药股份有限公司 一种降低了毒性杂质含量的酪氨酸激酶抑制剂的原料药
CN111138414A (zh) * 2018-11-05 2020-05-12 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的晶型及其制备方法
WO2021037185A1 (zh) * 2019-08-30 2021-03-04 江苏恒瑞医药股份有限公司 一种低杂质含量的酪氨酸激酶抑制剂
CN112759583B (zh) * 2020-12-31 2022-10-11 河南省医药科学研究院 包含呋喃基的喹啉类衍生物及其制备方法和用途
CN112625025B (zh) * 2020-12-31 2022-03-29 河南省医药科学研究院 吡啶基取代的喹啉类衍生物及其制备方法和用途
CN114890930A (zh) * 2022-04-18 2022-08-12 重庆医药高等专科学校 一种吡咯替尼中间体（r，e）-3-（1-甲基吡咯烷-2-基）丙烯酸盐酸盐合成方法
CN114920683B (zh) * 2022-06-24 2024-03-26 苏州富士莱医药股份有限公司 一种Boc-脯氨醛以及（R,E）-（1-甲基吡咯烷-2-基）丙烯酸的制备方法
CN115073344B (zh) * 2022-06-24 2024-03-26 苏州富士莱医药股份有限公司 一种r-(1-叔丁氧羰基吡咯烷-2-基)丙烯酸的制备方法及其应用
EP4682143A1 (en) * 2023-03-10 2026-01-21 Convalife Pharmaceuticals Co., Ltd. Pharmaceutical composition containing egfr inhibitor, and preparation method therefor and use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670579B2 (en) * 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
CL2004000016A1 (es) * 2003-01-21 2005-04-15 Wyeth Corp Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina.
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
CN101128425B (zh) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Iap二聚体抑制剂
AR053364A1 (es) * 2005-04-20 2007-05-02 Smithkline Beecham Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
RU2007140957A (ru) * 2005-05-25 2009-06-27 Вайет (Us) Способы синтеза производных 6-алкиламинохинолинов
JP2007084530A (ja) * 2005-08-22 2007-04-05 Sankyo Co Ltd インダノール誘導体を含有する医薬組成物
WO2010048477A2 (en) * 2008-10-24 2010-04-29 Wyeth Llc Improved process for preparation of coupled products from 4-amino-3-cyanoquinolines using stabilized intermediates
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
EP2485678A4 (en) * 2009-10-07 2013-04-03 Univ Cornell Coferons and methods of making and using them
US8735409B2 (en) * 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CN102382106A (zh) * 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
CN102675287A (zh) 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
WO2013152135A1 (en) * 2012-04-04 2013-10-10 Dawei Zhang Substituted quinolines as bruton's tyrosine kinases inhibitors
CN104119350B (zh) * 2013-04-28 2017-04-12 广东东阳光药业有限公司 氨基喹唑啉类衍生物及其盐和使用方法
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN105330646B (zh) * 2015-12-04 2019-05-24 上海勋和医药科技有限公司 一种抗肿瘤药马来酸来那替尼的制备方法

Also Published As

Publication number Publication date
DK3447051T3 (da) 2022-01-17
US20200392111A1 (en) 2020-12-17
PT3447051T (pt) 2022-01-06
HUE057402T2 (hu) 2022-05-28
BR112018071617A2 (pt) 2019-02-19
CN108290867A (zh) 2018-07-17
JP6947749B2 (ja) 2021-10-13
EP3447051A4 (en) 2019-11-27
JP2019520305A (ja) 2019-07-18
US10793548B2 (en) 2020-10-06
ES2903416T3 (es) 2022-04-01
US20190127350A1 (en) 2019-05-02
US11198683B2 (en) 2021-12-14
TW201738236A (zh) 2017-11-01
EP3447051B1 (en) 2021-12-15
CN108290867B (zh) 2022-02-08
TWI739825B (zh) 2021-09-21
WO2017186140A1 (zh) 2017-11-02
EP3447051A1 (en) 2019-02-27
CA3021471A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
IL279258B (en) tyrosine kinase inhibitors
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
PT3447051T (pt) Método para preparar um inibidor de tirosina quinase e um derivado do mesmo
IL275207A (en) An oxyfluoropiperidine derivative as a kinase inhibitor
PL3218378T3 (pl) Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
SG11202004918XA (en) Amino-fluoropiperidine derivative as kinase inhibitor
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
PT3461821T (pt) Compostos de indol carboxamida úteis como inibidores de quinase
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
IL304547A (en) 3-substituted benzamide derivatives as kinase inhibitors
PL3689351T3 (pl) Pochodna chinoliny i zastosowanie jej jako inhibitor kinazy tyrozynowej
ZA201802141B (en) Egfr kinase inhibitor and preparation method and use thereof
ZA201808238B (en) Certain protein kinase inhibitors
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
IL247867A0 (en) Modified oxazole-diazespiroalkane derivatives as spleen tyrosine kinase inhibitors
EP3699177A4 (en) METHOD OF MANUFACTURING A TYROSINKINAS INHIBITOR AND INTERMEDIATE THEREOF
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
HK40029221A (en) Kinase inhibitors and methods for making and using
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors